BEGIN:VCALENDAR VERSION:2.0 PRODID:-//CITI Program - ECPv6.17.4.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:CITI Program X-ORIGINAL-URL:https://about.citiprogram.org X-WR-CALDESC:Events for CITI Program REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20270314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20271107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20260929T151500 DTEND;TZID=America/New_York:20260929T161500 DTSTAMP:20260901T155708Z CREATED:20260901T155708Z LAST-MODIFIED:20260901T155708Z UID:62654-1790694900-1790698500@about.citiprogram.org SUMMARY:Free Webinar Replay - Navigating the Intersection of Open Science and Responsible Conduct of Research DESCRIPTION:Navigating the Intersection of Open Science and Responsible Conduct of Research\nTuesday\, September 29\, 2026 at 3:15 p.m. ET\nThis previously released webinar serves as an introduction to open science principles and practices. It describes what open science is\, how it is related to frameworks for Responsible Conduct of Research\, and the primary rationale for why it is valuable. It then reviews a set of core open science practices—open data\, open code\, open materials\, preregistration\, and open access publishing—highlighting both the benefits and potential limitations of each. The webinar emphasizes that engaging in open science practices is not “all or nothing” and is something that researchers can — and should — begin right away. \nRegister for additional free live webinars and available webinar replays. \n\n \n \n\n\n \n \n \n \n \n This Webinar Has Closed\n \n \n \n Click below to browse our other upcoming webinars. \n \n\n\n\n \n Webinars Catalog URL:https://about.citiprogram.org/event/free-webinar-replay-navigating-the-intersection-of-open-science-and-responsible-conduct-of-research/ LOCATION:Online ATTACH;FMTTYPE=image/png:https://about.citiprogram.org/wp-content/uploads/2021/11/citi-program-logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20261007T120000 DTEND;TZID=America/New_York:20261007T130000 DTSTAMP:20260828T133341Z CREATED:20260828T133341Z LAST-MODIFIED:20260828T133341Z UID:63165-1791374400-1791378000@about.citiprogram.org SUMMARY:Clinical Center Ethics Grand Rounds: Ethics Of Reducing the Use of Animals In Research DESCRIPTION:Join the NIH for the “Clinical Center Ethics Grand Rounds: Ethics Of Reducing the Use of Animals In Research” session on October 7\, 2026. This session will be presented by Jayantha Bhattacharya\, MD\, Director at the National Institutes of Health. \nVisit the event page for more information. URL:https://about.citiprogram.org/event/clinical-center-ethics-grand-rounds-ethics-of-reducing-the-use-of-animals-in-research/ LOCATION:Main NIH Campus; Building 10 (Clinical Center); Lipsett Amphitheater\, 10 Center Drive\, Bethesda\, MD\, 20892\, United States ATTACH;FMTTYPE=image/png:https://about.citiprogram.org/wp-content/uploads/2025/09/nih-logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20261007T130000 DTEND;TZID=America/New_York:20261007T140000 DTSTAMP:20260828T135800Z CREATED:20260828T135800Z LAST-MODIFIED:20260828T135800Z UID:63168-1791378000-1791381600@about.citiprogram.org SUMMARY:Town Hall – Biocompatibility and Toxicological Risk Assessment DESCRIPTION:The U.S. Food and Drug Administration (FDA) will host a town hall for industry stakeholders and other interested parties to discuss toxicological risk assessments used to address biocompatibility endpoints for medical devices. The session will focus on methods and considerations for conducting toxicological risk assessments in accordance with FDA-recognized standards\, as well as examples of common deviations encountered during the evaluation process. \nVisit the event page for more information. URL:https://about.citiprogram.org/event/town-hall-biocompatibility-and-toxicological-risk-assessment/ LOCATION:Online ATTACH;FMTTYPE=image/png:https://about.citiprogram.org/wp-content/uploads/2025/04/fda-logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20261007T150000 DTEND;TZID=America/New_York:20261007T160000 DTSTAMP:20260828T132043Z CREATED:20260828T132043Z LAST-MODIFIED:20260828T132043Z UID:63163-1791385200-1791388800@about.citiprogram.org SUMMARY:Beyond the Lab: Insights into Clinical Development in Pharma DESCRIPTION:Join the NIH for the “Beyond the Lab: Insights into Clinical Development in Pharma” workshop\, presented by Delphine Lissa\, on October 7\, 2026. This webinar is part of NCI’s Science-Based Non-Academic Careers (SNAC) virtual workshop series\, which assists fellows\, staff scientists\, and staff clinicians in exploring non-academic career paths with greater clarity and confidence. \nVisit the event page for more information. URL:https://about.citiprogram.org/event/beyond-the-lab-insights-into-clinical-development-in-pharma/ LOCATION:Online ATTACH;FMTTYPE=image/png:https://about.citiprogram.org/wp-content/uploads/2025/09/nih-logo.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20261014T120000 DTEND;TZID=America/New_York:20261014T130000 DTSTAMP:20260902T154920Z CREATED:20260902T154920Z LAST-MODIFIED:20260902T154920Z UID:63199-1791979200-1791982800@about.citiprogram.org SUMMARY:Navigating the FDA Bayesian Draft Guidance: Design\, Analysis\, and Review Considerations DESCRIPTION:Hosted by the FDA’s Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA)\, this event focuses on the Agency’s January 2026 draft guidance\, “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products\,” which was published to address a PDUFA VII commitment. The guidance outlines key considerations for applying Bayesian methods in clinical trials\, including success criteria and operating characteristics\, the use of external information in prior distributions\, estimands and missing data\, software and computational considerations\, and the documentation and reporting of Bayesian analyses. \nThe program begins with a required pre-recorded video that participants may complete at their own pace before the live panel discussion. The recording provides an overview of the guidance and its implications for the design of clinical trials that use Bayesian methodologies. \nIntended Audience \nClinical trial professionals\, regulatory science professionals\, or regulatory affairs professionals involved in clinical trials and studies where Bayesian approaches may be used. \nTopics Covered \n\nA brief introduction to Bayesian approaches\nSuccess criteria and operating characteristics in Bayesian trials\nConsiderations for prior distributions\nAdditional topics including missing data and estimands\, software usage\, documenting and reporting expectations for Bayesian analyses\nDescriptions of specific settings where Bayesian methods have been previously used.\n\nVisit the event page for more information. URL:https://about.citiprogram.org/event/navigating-the-fda-bayesian-draft-guidance-design-analysis-and-review-considerations/ LOCATION:Online ATTACH;FMTTYPE=image/png:https://about.citiprogram.org/wp-content/uploads/2025/04/fda-logo.png END:VEVENT END:VCALENDAR